Drug Information

Drug General Information
Drug ID
D09DJC
Former ID
DNCL002746
Drug Name
IRX4204
Drug Type
Small molecular drug
Indication Prostate cancer [ICD9: 185; ICD10:C61] Phase 1 [525182]
Company
Io Therapeutics
Formula
C24H32O2
PubChem Compound ID
9863341
Target and Pathway
Target(s) Retinoic acid receptor RXR-gamma Target Info Modulator
KEGG Pathway PPAR signaling pathway
Thyroid hormone signaling pathway
Adipocytokine signaling pathway
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
Small cell lung cancer
Non-small cell lung cancer
Pathway Interaction Database Regulation of Androgen receptor activity
RXR and RAR heterodimerization with other nuclear receptor
Retinoic acid receptors-mediated signaling
a6b1 and a6b4 Integrin signaling
Reactome Nuclear Receptor transcription pathway
WikiPathways Vitamin A and Carotenoid Metabolism
Adipogenesis
Nuclear Receptors
References
Ref 525182ClinicalTrials.gov (NCT02438215) Study of IRX4204 for Treatment of Early Parkinson's Disease. U.S. National Institutes of Health.